Suchergebnisse - "Laharie, David"

PubPharm (290)

31

Management of Inflammatory Bowel Disease in Patients with Current or Past Malignancy

enthalten in: Cancers | 2023

von Poullenot, F. | Laharie, D.

32

Correction : Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study

enthalten in: BMC gastroenterology | 2023

von Rayer, C. | Nachury, M. | Bourreille, A. | +10

ErratumFor: BMC Gastroenterol. 2022 Dec 1;22(1):498. - PMID 36457080

33

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

enthalten in: BMC gastroenterology | 2023

von Rayer, C. | Nachury, M. | Bourreille, A. | +10

34

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

enthalten in: BMC gastroenterology | 2023

von Rayer, C. | Nachury, M. | Bourreille, A. | +10

35

The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics

enthalten in: Frontiers in immunology | 2023

von Lelong, M. | Josien, R. | Coste-Burel, M. | +23

36

The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study

enthalten in: Journal of Crohn's & colitis | 2023

von Amiot, A. | Rahier, J. | Baert, F. | +110

ErratumIn: J Crohns Colitis. 2023 Jun 16;17(6):1025. - PMID 36808222

37

Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease : the COMBIO study

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Guillo, L. | Flachaire, B. | Avouac, J. | +65

38

Editorial : selecting therapy for ulcerative colitis-think a step ahead

enthalten in: Alimentary pharmacology & therapeutics | 2023

von Laharie, D. | Riviere, P.

CommentOn: Aliment Pharmacol Ther. 2023 Jan;57(1):117-126. - PMID 36282200

39

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT) : a randomised, placebo-controlled, double-blind, phase 3 trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Sandborn, W. | Panés, J. | Danese, S. | +14

40

Editorial : selecting therapy for ulcerative colitis—think a step ahead

enthalten in: Alimentary Pharmacology & Therapeutics | 2023

von Laharie, D. | Riviere, P.